Do You Consider Cost When Prescribing a Drug?

June 12, 2019

The US Food and Drug Administration recently approved onasemnogene abeparvovec-xioi (Zolgensma, AveXis Inc, a Novartis company), the first gene therapy for children younger than age 2 who have spinal muscular atrophy.

The price tag for a one-time infusion: more than $2 million. This makes Zolgensma the world's most expensive drug, although the company said it is working closely with insurers to create 5-year outcomes-based agreements and novel pay-over-time options. Divided over 5 years, the drug costs $425,000 per year.

Zolgensma's price may be a new height, but drug costs have long been in the national spotlight. It remains to be seen whether political action will change the status quo.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.